Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
Alumis Inc. recently reported past Phase 3 ONWARD1 and ONWARD2 trial results showing envudeucitinib, its oral TYK2 inhibitor, delivered high skin clearance, rapid itch relief, and quality-of-life ...
Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
4d
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & Co., Inc. (NYSE:MRK) announced positive Phase 3 CORALreef AddOn trial ...
Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results